These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 20523864)

  • 41. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation.
    Lafuente-Lafuente C; Valembois L; Bergmann JF; Belmin J
    Cochrane Database Syst Rev; 2015 Mar; (3):CD005049. PubMed ID: 25820938
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of Angiotensin converting enzyme inhibitors and Angiotensin receptor blockers on patients following ablation of atrial fibrillation.
    Park JH; Oh YS; Kim JH; Chung WB; Oh SS; Lee DH; Choi YS; Shin WS; Park CS; Youn HJ; Chung WS; Lee MY; Seung KB; Rho TH; Kim JH; Hong SJ
    Korean Circ J; 2009 May; 39(5):185-9. PubMed ID: 19949577
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment of atrial fibrillation.
    Bajpai A; Savelieva I; Camm AJ
    Br Med Bull; 2008; 88(1):75-94. PubMed ID: 19059992
    [TBL] [Abstract][Full Text] [Related]  

  • 44. New antiarrhythmic drugs for prevention of atrial fibrillation.
    Goldstein RN; Stambler BS
    Prog Cardiovasc Dis; 2005; 48(3):193-208. PubMed ID: 16271945
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Atrial fibrillation: new horizons.
    Kuo CT; Luqman N; Lin KH; Lee YS
    Chang Gung Med J; 2003 Oct; 26(10):712-21. PubMed ID: 14717205
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Role of insulin-sensitizing property of telmisartan, a commercially available angiotensin II type 1 receptor blocker in preventing the development of atrial fibrillation.
    Yamagishi S; Takenaka K; Inoue H
    Med Hypotheses; 2006; 66(1):118-20. PubMed ID: 16154710
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Renin-angiotensin system inhibitors prevent the recurrence of atrial fibrillation: a meta-analysis of randomized controlled trials.
    Han M; Zhang Y; Sun S; Wang Z; Wang J; Xie X; Gao M; Yin X; Hou Y
    J Cardiovasc Pharmacol; 2013 Oct; 62(4):405-15. PubMed ID: 23921300
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antiarrhythmic drugs in atrial fibrillation: do they have a future?
    Angaran P; Dorian P
    Can J Cardiol; 2013 Oct; 29(10):1158-64. PubMed ID: 23906791
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Primary prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with end-stage renal disease undergoing dialysis.
    Lin TT; Yang YH; Liao MT; Tsai CT; Hwang JJ; Chiang FT; Chen PC; Lin JL; Lin LY
    Kidney Int; 2015 Aug; 88(2):378-85. PubMed ID: 25807037
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Use of Flecainide for the Treatment of Atrial Fibrillation.
    Echt DS; Ruskin JN
    Am J Cardiol; 2020 Apr; 125(7):1123-1133. PubMed ID: 32044037
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The role of renin-angiotensin system blockade therapy in the prevention of atrial fibrillation: a meta-analysis of randomized controlled trials.
    Zhang Y; Zhang P; Mu Y; Gao M; Wang JR; Wang Y; Su LQ; Hou YL
    Clin Pharmacol Ther; 2010 Oct; 88(4):521-31. PubMed ID: 20811347
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Current management of symptomatic atrial fibrillation.
    Haghi D; Schumacher B
    Am J Cardiovasc Drugs; 2001; 1(2):127-39. PubMed ID: 14728042
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Current antiarrhythmic drug therapy in atrial fibrillation].
    Goette A
    Dtsch Med Wochenschr; 2010 Mar; 135 Suppl 2():S33-7. PubMed ID: 20221976
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Epidemiology and therapy of atrial fibrillation].
    Capucci A; Aschieri D; Villani GQ
    Ann Ital Med Int; 1996 Oct; 11 Suppl 2():5S-10S. PubMed ID: 9004821
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The Role of Pharmacogenetics in Atrial Fibrillation Therapeutics: Is Personalized Therapy in Sight?
    Darbar D
    J Cardiovasc Pharmacol; 2016 Jan; 67(1):9-18. PubMed ID: 25970841
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation.
    Lafuente-Lafuente C; Mouly S; Longas-Tejero MA; Bergmann JF
    Cochrane Database Syst Rev; 2007 Oct; (4):CD005049. PubMed ID: 17943835
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Atrial fibrillation and heart failure: natural history and pharmacological treatment.
    Savelieva I; John Camm A
    Europace; 2004 Sep; 5 Suppl 1():S5-19. PubMed ID: 15450275
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The role of the renin-angiotensin system in atrial fibrillation and the therapeutic effects of ACE-Is and ARBS.
    Novo G; Guttilla D; Fazio G; Cooper D; Novo S
    Br J Clin Pharmacol; 2008 Sep; 66(3):345-51. PubMed ID: 18782141
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Revisiting an Underrecognized Strategy for Rhythm Management: Hybrid Therapy for Patients who Convert from Atrial Fibrillation to Flutter on Antiarrhythmic Drugs.
    Riad FS; Waldo AL
    J Innov Card Rhythm Manag; 2019 Oct; 10(10):3842-3847. PubMed ID: 32477703
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical Outcomes of Rate vs Rhythm Control for Atrial Fibrillation in Older People: A Systematic Review and Meta-Analysis.
    Depoorter L; Sels L; Deschodt M; Van Grootven B; Van der Linden L; Tournoy J
    Drugs Aging; 2020 Jan; 37(1):19-26. PubMed ID: 31745834
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.